JPMorgan assumed coverage of Myriad Genetics with an Underweight rating and $18 price target. The analyst maintained the firm’s current rating, price target, and estimates.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics enters research collaboration with MD Anderson
- Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
- Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
- Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics